Remdesivir Patent Expiration

Remdesivir is Used for treatment of COVID-19 in hospitalized and non-hospitalized adults and pediatric patients when concurrent use of other medications is not recommended. It was first introduced by Gilead Sciences Inc in its drug Veklury on Oct 22, 2020.


Remdesivir Patents

Given below is the list of patents protecting Remdesivir, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Veklury US11491169

(Pediatric)

Remdesivir treatment methods Nov 28, 2041 Gilead Sciences Inc
Veklury US11903953

(Pediatric)

Remdesivir treatment methods Nov 28, 2041 Gilead Sciences Inc
Veklury US11975012

(Pediatric)

Remdesivir treatment methods Nov 28, 2041 Gilead Sciences Inc
Veklury US11491169 Remdesivir treatment methods May 28, 2041 Gilead Sciences Inc
Veklury US11903953 Remdesivir treatment methods May 28, 2041 Gilead Sciences Inc
Veklury US11975012 Remdesivir treatment methods May 28, 2041 Gilead Sciences Inc
Veklury US10675296

(Pediatric)

Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections Jan 10, 2039 Gilead Sciences Inc
Veklury US11266681

(Pediatric)

Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections Jan 10, 2039 Gilead Sciences Inc
Veklury US11975017

(Pediatric)

Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections Jan 10, 2039 Gilead Sciences Inc
Veklury US10675296 Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections Jul 10, 2038 Gilead Sciences Inc
Veklury US11266681 Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections Jul 10, 2038 Gilead Sciences Inc
Veklury US11975017 Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections Jul 10, 2038 Gilead Sciences Inc
Veklury US10695361

(Pediatric)

Methods for treating arenaviridae and coronaviridae virus infections Mar 16, 2037 Gilead Sciences Inc
Veklury US11007208

(Pediatric)

Methods for treating arenaviridae and coronaviridae virus infections Mar 16, 2037 Gilead Sciences Inc
Veklury US11382926

(Pediatric)

Methods for treating Arenaviridae and Coronaviridae virus infections Mar 16, 2037 Gilead Sciences Inc
Veklury US10695361 Methods for treating arenaviridae and coronaviridae virus infections Sep 16, 2036 Gilead Sciences Inc
Veklury US11007208 Methods for treating arenaviridae and coronaviridae virus infections Sep 16, 2036 Gilead Sciences Inc
Veklury US11382926 Methods for treating Arenaviridae and Coronaviridae virus infections Sep 16, 2036 Gilead Sciences Inc
Veklury US9724360

(Pediatric)

Methods for treating Filoviridae virus infections Apr 29, 2036 Gilead Sciences Inc
Veklury US9949994

(Pediatric)

Methods for treating Filoviridae virus infections Apr 29, 2036 Gilead Sciences Inc
Veklury US9724360 Methods for treating Filoviridae virus infections Oct 29, 2035 Gilead Sciences Inc
Veklury US9949994 Methods for treating Filoviridae virus infections Oct 29, 2035 Gilead Sciences Inc
Veklury US11492353

(Pediatric)

Methods and compounds for treating Paramyxoviridae virus infections Jun 08, 2032 Gilead Sciences Inc
Veklury US10065958

(Pediatric)

Methods and compounds for treating Paramyxoviridae virus infections Mar 16, 2032 Gilead Sciences Inc
Veklury US11492353 Methods and compounds for treating Paramyxoviridae virus infections Dec 08, 2031 Gilead Sciences Inc
Veklury US10065958 Methods and compounds for treating Paramyxoviridae virus infections Sep 16, 2031 Gilead Sciences Inc
Veklury US8008264

(Pediatric)

1′-substituted carba-nucleoside analogs for antiviral treatment Mar 06, 2030 Gilead Sciences Inc
Veklury US8318682

(Pediatric)

1′substituted carba-nucleoside analogs for antiviral treatment Oct 22, 2029 Gilead Sciences Inc
Veklury USRE46762

(Pediatric)

1′-substituted carba-nucleoside analogs for antiviral treatment Oct 22, 2029 Gilead Sciences Inc
Veklury US8008264 1′-substituted carba-nucleoside analogs for antiviral treatment Sep 06, 2029 Gilead Sciences Inc
Veklury US8318682 1′substituted carba-nucleoside analogs for antiviral treatment Apr 22, 2029 Gilead Sciences Inc
Veklury USRE46762 1′-substituted carba-nucleoside analogs for antiviral treatment Apr 22, 2029 Gilead Sciences Inc



A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Remdesivir's patents.

Given below is the list recent legal activities going on the following patents of Remdesivir.

Activity Date Patent Number
Patent litigations
Payment of Maintenance Fee, 12th Year, Large Entity 15 May, 2024 US8318682
transaction for FDA Determination of Regulatory Review Period 29 Feb, 2024 US9724360
transaction for FDA Determination of Regulatory Review Period 29 Feb, 2024 US9949994
transaction for FDA Determination of Regulatory Review Period 29 Feb, 2024 US8318682
transaction for FDA Determination of Regulatory Review Period 29 Feb, 2024 US8008264
transaction for FDA Determination of Regulatory Review Period 29 Feb, 2024 US10065958
transaction for FDA Determination of Regulatory Review Period 23 Feb, 2024 US9724360
transaction for FDA Determination of Regulatory Review Period 23 Feb, 2024 US10065958
transaction for FDA Determination of Regulatory Review Period 23 Feb, 2024 US8008264
transaction for FDA Determination of Regulatory Review Period 23 Feb, 2024 US8318682


Remdesivir's Family Patents

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List